Booster influenza vaccination confers additional immune responses in an elderly, rural community-dwelling population

Published:November 14, 2017DOI:


      • Two doses of influenza vaccine were administered to the elderly aged 61-102 years.
      • Antibody responses 22 weeks after the vaccination were measured.
      • Seroprotection rates (PRs) against the A(H3N2) and B strains were maintained.
      • The PR against the A(H1N1)pdm09 strain in people aged 61-75 years did not decrease.
      This study aimed to examine the effects of a booster vaccination in elderly people using 2 doses of trivalent inactivated influenza vaccine during the 2012-2013 influenza epidemic. Seroprotection rates against the A(H1N1)pdm09 strain in younger elderly people (aged 61-75 years) and the A(H3N2) and B strains in both younger elderly people (aged 61-75 years) as well as very elderly people (aged 76-102 years) did not decrease at 22 weeks after vaccination. This approach confers long-lasting antibody responses and may be useful in clinical practice.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Infection Control
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • CDC
        Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
        MMWR. 2010; 59 (No. RR-8): 1-62
        • Goodwin K.
        • Viboud C.
        • Simonsen L.
        Antibody response to influenza vaccination in the elderly: a quantitative review.
        Vaccine. 2006; 24: 1159-1169
        • Sato M.
        • Saito R.
        • Tanabe N.
        • Nishikawa M.
        • Sasaki A.
        • Gejyo F.
        • et al.
        Antibody response to influenza vaccination in nursing home residents and healthcare workers during four successive seasons in Niigata, Japan.
        Infect Control Hosp Epidemiol. 2005; 26: 859-866
        • Matsushita M.
        • Takeuchi S.
        • Kumagai N.
        • Uehara Y.
        • Matsushita C.
        • Arise K.
        • et al.
        Prevaccination antibody titers can estimate the immune response to influenza vaccine in a rural community-dwelling elderly population.
        Vaccine. 2012; 30: 1101-1107
        • Skowronski D.M.
        • Tweed S.A.
        • De Serres G.
        Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?.
        J Infect Dis. 2008; 197: 490-502
        • Hara M.
        • Tanaka K.
        • Hirota Y.
        Immune response to influenza vaccine in healthy adults and the elderly: association with nutritional status.
        Vaccine. 2005; 23: 1457-1463
        • Song J.Y.
        • Cheong H.J.
        • Hwang I.S.
        • Choi W.S.
        • Jo Y.M.
        • Park D.W.
        • et al.
        Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence.
        Vaccine. 2010; 28: 3929-3935
        • Sasaki S.
        • Sullivan M.
        • Narvaez C.F.
        • Holmes T.H.
        • Furman D.
        • Zheng N.Y.
        • et al.
        Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies.
        J Clin Invest. 2011; 121: 3109-3119